Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
It's been a great run, but Ozempic's spotlight could begin fading fast. New research strongly suggests a competing diabetes treatment from Eli Lilly (NYSE: LLY) is even better at helping patients manage their weight than the leading brand.
Recently, researchers from a data analytics business called Truveta made big waves with an independent study that compared the effectiveness of semaglutide, the active ingredient in Ozempic and Wegovy, with tirzepatide, the active ingredient in Mounjaro and Zepbound.
Image source: Getty Images.
Source Fool.com
